--- /home/parlparse/parldata/cmpages/wrans/answers2006-03-28b.html	2006-03-31 08:08:44.000000000 +0100
+++ /home/parlparse/parldata/tmp/patchtmp-answers2006-03-28b-U2jB8y.html	2006-03-31 08:59:49.980078711 +0100
@@ -11463,7 +11463,7 @@
 
 
 <a name="subhd_99">
-<a name="60328w35.html_sbhd6"><h3 align=center>Medicines and Healthcare Products Regulatory Agency</h3>
+<a name="60328w35.html_sbhd6"><h3 align=center>Medicines and Healthcare Products Regulatory Agency, Pharmaceutical Industry</h3>
 
 
 <p><a name="qn_140"><a name="60328w35.html_wqn7"><b> Chris Grayling: </b> 
@@ -11481,8 +11481,6 @@
 
 <i>28 Mar 2006 : Column 964W&#151;continued</i><br>
 <a name="subhd_100">
-<a name="60328w36.html_sbhd0"><h3 align=center>Pharmaceutical Industry</h3>
-
 
 <p><a name="60328w36.html_wqn0"><b>  </b> 
 <a name="qnpa_13">(2) whether she has satisfied herself that the level of protection under the Public Interest Disclosure Act 1998 offers sufficient protection to employees within the pharmaceutical sector; and whether she plans to review the working of the Act within the sector;  [59165]
